Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 11.77 as of 2026-09-12T00:15:25.511Z.
Consensus retrieved: 2026-09-11T00:18:44.694Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-12T00:15:25.511Z.
Quote observation: 2026-09-11T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7a160eba2e6f1c5e8849d236595523f5364ec24b92cdcee057594ff20d8a7a33
Forward PE Ratio (11.77) = Dated Quote Price ($53.91) / Consensus Forward EPS ($4.58)
FORWARD PE RATIO
11.77
SECTOR MEDIAN · HEALTHCARE
18.95
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-37.91%
vs the sector median at left
The Cooper Companies, Inc.
Market Cap
$10.51B
Forward PE Ratio
11.77
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| The Cooper Companies, Inc. (COO) | $10.51B | 11.77 |
| Universal Health Services, Inc. (UHS)vs › | $10.58B | 7.76 |
| Molina Healthcare, Inc. (MOH)vs › | $10.66B | N/A |
| Tempus AI, Inc. (TEM)vs › | $10.34B | N/A |
| Align Technology, Inc. (ALGN)vs › | $10.80B | 13.36 |
| The Ensign Group, Inc. (ENSG)vs › | $10.14B | 22.32 |
| Henry Schein, Inc. (HSIC)vs › | $10.07B | 16.41 |
| Globus Medical, Inc. (GMED)vs › | $10.01B | 14.84 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.94B | 38.31 |
| Bio-Techne Corporation (TECH)vs › | $11.29B | 35.09 |
Trailing P/E
18.4
reported TTM EPS
Forward P/E
11.8
consensus EPS · fiscal year ending 2026-10-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $4.58 implies +56.3% EPS growth vs the reported trailing $2.93.
At the dated quote price of $53.91, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-10-31 | $4.58 | $4.56 – $4.62 | 11 | 11.8x |
| 2027-10-31 | $4.85 | $4.78 – $4.93 | 11 | 11.1x |
| 2028-10-31 | $5.26 | $4.33 – $5.91 | 7 | 10.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
